个性化文献订阅>文章检索

文章名     作者     期刊名     摘要     卷     期         如果没有找到您所需要的文献，请点击 ——此处申请     共11条记录   Belimumab therapy for systemic lupus erythematosus and potential treatment of rheumatoid arthritis [作者：Ding, CH; Li, R; Xu, JH; Cicuttini, F; Jones, G,期刊：Drug Development Research, 页码：623-633 , 文章类型： Article，,卷期：2011年72-7] B-lymphocyte stimulator (BLyS) maintains the survival of B cells, and is elevated in serum or locally in patients with systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA). Belimumab (LymphoStat-B) is a fully... Clinical profile of cyclosporine in dermatology [作者：Colombo, D; Poggi, S,期刊：Drug Development Research, 页码：634-646 , 文章类型： Article，,卷期：2011年72-7] Cyclosporine is one of the most effective agents available for the treatment of psoriasis. It is also widely used in atopic dermatitis and other dermatological disorders. Recent consensus guidelines for psoriasis recomme... Current management of Behcet's syndrome [作者：Nowatzky, J; Yazici, Y,期刊：Drug Development Research, 页码：647-656 , 文章类型： Article，,卷期：2011年72-7] Behcet's syndrome (BS), or Behcet's disease (BD), is a multisystem inflammatory disorder that mainly affects population clusters along the Old Silk Road; however, it has been reported worldwide. The disease is currently ... Biomarkers: improving the cost-effectiveness of biological drugs for autoimmune disorders [作者：Gurwitz, D,期刊：Drug Development Research, 页码：549-552 , 文章类型： Editorial Material，,卷期：2011年72-7] Biological drugs are gradually becoming the treatment of choice for chronic autoimmune diseases. However, their high costs are a key healthcare concern limiting their attractiveness for payers. This can, in part, be offs... Canakinumab for the treatment of adult and pediatric cryopyrin-associated periodic syndromes (CAPS) [作者：Patel, AM; Torok, KS,期刊：Drug Development Research, 页码：553-560 , 文章类型： Article，,卷期：2011年72-7] The cryopyrin-associated periodic syndromes (CAPS) comprise three rare autoinflammatory disorders: familial cold autoinflammatory syndrome, MuckleWells syndrome, and neonatal-onset multisystem inflammatory disorder. A mu... Current drugs in systemic lupus erythematosus [作者：Yu, YY; La Cava, A,期刊：Drug Development Research, 页码：561-572 , 文章类型： Article，,卷期：2011年72-7] Systemic lupus erythematosus (SLE) is an autoimmune disease with heterogeneous presentation and clinical manifestations. These aspects represent a problem in the treatment of the disease. Nonspecific medications for SLE ... The lymphocyte potassium channels Kv1.3 and KCa3.1 as targets for immunosuppression [作者：Lam, J; Wulff, H,期刊：Drug Development Research, 页码：573-584 , 文章类型： Article，,卷期：2011年72-7] The voltage-gated Kv1.3 and the calcium-activated KCa3.1 potassium channel modulate many calcium-dependent cellular processes in immune cells, including T-cell activation and proliferation and have therefore been propose... T-cell targeted therapies in autoimmune diseases [作者：Alnaimat, F; Sidhu, P; Sarkar, S,期刊：Drug Development Research, 页码：585-597 , 文章类型： Article，,卷期：2011年72-7] Significant advances have been made during the past decade in the understanding of autoimmune diseases and in the development of therapeutics targeting various immune pathways. T-cell-mediated immune dysregulation occurs... Emergence of small-molecule CXCR4 antagonists as novel immune and hematopoietic system regulatory agents [作者：Wilson, LJ; Liotta, DC,期刊：Drug Development Research, 页码：598-602 , 文章类型： Article，,卷期：2011年72-7] The chemokine CXCR4 receptor is a G-protein-coupled receptor that has multiple functions in normal physiologies involving the hematopoietic and immune systems. Although the CXCR4 receptor was initially discovered as one ... Certolizumab pegol therapy of rheumatoid arthritis: Overview [作者：Zidi, I; Mnif, W; Bouaziz, A; Ben Amor, N,期刊：Drug Development Research, 页码：603-614 , 文章类型： Article，,卷期：2011年72-7] First-line treatment for moderate to severe rheumatoid arthritis (RA) has been the use of disease-modifying anti-rheumatic drugs (DMARDs), e.g., methotrexate. Because of the cases of failure reported to respond to availa... Anti-tumor necrosis factor-a therapies for immune-mediated and inflammatory skin diseases [作者：Dessinioti, C; Stratigos, AJ; Katsambas, A; Antoniou, C,期刊：Drug Development Research, 页码：615-622 , 文章类型： Article，,卷期：2011年72-7] Anti-tumor necrosis factor-a (TNF-a) therapies, also called biologic therapies or immunotherapies, are being used increasingly in dermatology, rheumatology, and gastroenterology in the context of established and emerging...